1. Home
  2. AVNW vs SABS Comparison

AVNW vs SABS Comparison

Compare AVNW & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aviat Networks Inc.

AVNW

Aviat Networks Inc.

HOLD

Current Price

$20.79

Market Cap

278.2M

Sector

Technology

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.58

Market Cap

280.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVNW
SABS
Founded
2006
2014
Country
United States
United States
Employees
N/A
86
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
278.2M
280.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
AVNW
SABS
Price
$20.79
$3.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$34.50
$10.75
AVG Volume (30 Days)
134.2K
914.7K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.29
N/A
Revenue
$243,858,000.00
N/A
Revenue This Year
$5.59
N/A
Revenue Next Year
$7.03
N/A
P/E Ratio
$71.59
N/A
Revenue Growth
0.56
N/A
52 Week Low
$13.92
$1.85
52 Week High
$27.02
$6.60

Technical Indicators

Market Signals
Indicator
AVNW
SABS
Relative Strength Index (RSI) 52.29 43.75
Support Level $20.65 $3.42
Resistance Level $22.95 $4.10
Average True Range (ATR) 1.13 0.21
MACD -0.13 -0.04
Stochastic Oscillator 30.06 17.54

Price Performance

Historical Comparison
AVNW
SABS

About AVNW Aviat Networks Inc.

Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: